Inobrodib
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a Kd of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR) - and C-MYC-regulated gene expression[1].
Product Specifications
CAS Number
[2222941-37-7]
Product Name Alternative
CCS1477
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CCS-1477.html
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(C2=CC=C(F)C(F)=C2)[C@H](C3=NC4=CC(C5=C(C)ON=C5C)=CC=C4N3[C@H]6CC[C@H](OC)CC6)CCC1
Molecular Formula
C30H32F2N4O3
Molecular Weight
534.60
Precautions
H315, H319, H335
References & Citations
[1]Rasool RU, et al. Toppling the HAT to Treat Lethal Prostate Cancer. Cancer Discov. 2021;11 (5) :1011-1013.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RNF138 (NARF, E3 Ubiquitin-protein Ligase RNF138, Nemo-like Kinase-associated RING Finger Protein, RING Finger Protein 138, MGC8758) (MaxLight 405) discontinued